Kala Pharmaceuticals Inc (KALA) - Net Assets
Based on the latest financial reports, Kala Pharmaceuticals Inc (KALA) has net assets worth $7.00 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.49 Million) and total liabilities ($2.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore KALA operating cash flow to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.00 Million |
| % of Total Assets | 73.72% |
| Annual Growth Rate | 34.37% |
| 5-Year Change | -58.37% |
| 10-Year Change | N/A |
| Growth Volatility | 477.34 |
Kala Pharmaceuticals Inc - Net Assets Trend (2013–2025)
This chart illustrates how Kala Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore KALA total asset value for the complete picture of this company's asset base.
Annual Net Assets for Kala Pharmaceuticals Inc (2013–2025)
The table below shows the annual net assets of Kala Pharmaceuticals Inc from 2013 to 2025. For live valuation and market cap data, see how much is Kala Pharmaceuticals Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $7.00 Million | -43.27% |
| 2024-12-31 | $12.33 Million | +64.34% |
| 2023-12-31 | $7.50 Million | -60.45% |
| 2022-12-31 | $18.97 Million | +12.91% |
| 2021-12-31 | $16.80 Million | -83.20% |
| 2020-12-31 | $100.00 Million | +236.77% |
| 2019-12-31 | $29.69 Million | -71.72% |
| 2018-12-31 | $104.99 Million | +17.07% |
| 2017-12-31 | $89.68 Million | +202.18% |
| 2016-12-31 | $-87.76 Million | -1414.97% |
| 2015-12-31 | $-5.79 Million | -277.59% |
| 2014-12-31 | $3.26 Million | +1514.85% |
| 2013-12-31 | $202.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kala Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 67197300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $28.00K | 0.40% |
| Other Components | $701.87 Million | 10032.42% |
| Total Equity | $7.00 Million | 100.00% |
Kala Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Kala Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Laurion Mineral Exploration Inc
V:LME
|
$43.35 Million |
|
U.C.A. AG O.N.
F:UCA1
|
$43.36 Million |
|
Taiwan Wax Co Ltd
TWO:1742
|
$43.36 Million |
|
Viscom AG
XETRA:V6C
|
$43.36 Million |
|
BANXA HOLDINGS INC.
F:AC00
|
$43.31 Million |
|
INFAC Corporation
KO:023810
|
$43.30 Million |
|
Hsinjing Holding Co Ltd
TWO:3713
|
$43.29 Million |
|
Oricom Inc
KQ:010470
|
$43.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kala Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 12,332,000 to 6,996,000, a change of -5,336,000 (-43.3%).
- Net loss of 26,980,000 reduced equity.
- New share issuances of 10,934,000 increased equity.
- Other factors increased equity by 10,710,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-26.98 Million | -385.65% |
| Share Issuances | $10.93 Million | +156.29% |
| Other Changes | $10.71 Million | +153.09% |
| Total Change | $- | -43.27% |
Book Value vs Market Value Analysis
This analysis compares Kala Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.71x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.58x to 2.71x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.42 | $2.33 | x |
| 2014-12-31 | $6.74 | $2.33 | x |
| 2015-12-31 | $-16.76 | $2.33 | x |
| 2016-12-31 | $-253.89 | $2.33 | x |
| 2017-12-31 | $210.76 | $2.33 | x |
| 2018-12-31 | $196.21 | $2.33 | x |
| 2019-12-31 | $43.40 | $2.33 | x |
| 2020-12-31 | $95.46 | $2.33 | x |
| 2021-12-31 | $12.89 | $2.33 | x |
| 2022-12-31 | $12.48 | $2.33 | x |
| 2023-12-31 | $3.09 | $2.33 | x |
| 2024-12-31 | $2.23 | $2.33 | x |
| 2025-12-31 | $0.86 | $2.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kala Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -385.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.36x
- Recent ROE (-385.65%) is above the historical average (-672.71%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -5273.76% | -21306.00% | 0.01x | 35.01x | $-10.67 Million |
| 2014 | -593.53% | -4255.16% | 0.04x | 3.59x | $-19.69 Million |
| 2015 | 0.00% | -37071.11% | 0.01x | 0.00x | $-16.10 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-24.39 Million |
| 2017 | -47.07% | 0.00% | 0.00x | 1.29x | $-51.18 Million |
| 2018 | -63.57% | 0.00% | 0.00x | 2.10x | $-77.24 Million |
| 2019 | -317.75% | -1553.29% | 0.04x | 5.20x | $-97.32 Million |
| 2020 | -104.33% | -1639.85% | 0.03x | 2.22x | $-114.33 Million |
| 2021 | -848.64% | -1268.73% | 0.08x | 8.30x | $-144.29 Million |
| 2022 | -236.23% | -1151.64% | 0.04x | 4.58x | $-46.72 Million |
| 2023 | -562.35% | 0.00% | 0.00x | 7.46x | $-42.95 Million |
| 2024 | -312.29% | 0.00% | 0.00x | 4.50x | $-39.74 Million |
| 2025 | -385.65% | 0.00% | 0.00x | 1.36x | $-27.68 Million |
Industry Comparison
This section compares Kala Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,677,567
- Average return on equity (ROE) among peers: -58.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kala Pharmaceuticals Inc (KALA) | $7.00 Million | -5273.76% | 0.36x | $43.31 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $86.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $42.37 Million | -200.47% | 0.88x | $323.66 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $183.46 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $804.47 Million |
| Arbutus Biopharma Corp (ABUS) | $203.00 Million | -189.21% | 0.36x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-52.67 Million | 0.00% | 0.00x | $3.63 Billion |
About Kala Pharmaceuticals Inc
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical d… Read more